- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2045-2322
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Single-cell-led drug repurposing for Alzheimer’s disease ; volume:13 ; number:1 ; day:5 ; month:1 ; year:2023 ; pages:1-14 ; date:12.2023
Scientific reports ; 13, Heft 1 (5.1.2023), 1-14, 12.2023
- Creator
-
Parolo, Silvia
Mariotti, Federica
Bora, Pranami
Carboni, Lucia
Domenici, Enrico
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41598-023-27420-x
- URN
-
urn:nbn:de:101:1-2023031421253320893966
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 11:01 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Parolo, Silvia
- Mariotti, Federica
- Bora, Pranami
- Carboni, Lucia
- Domenici, Enrico
- SpringerLink (Online service)
Other Objects (12)
In silico repurposing of antipsychotic drugs for Alzheimer’s disease
Artificial intelligence framework identifies candidate targets for drug repurposing in Alzheimer’s disease
High-throughput target trial emulation for Alzheimer’s disease drug repurposing with real-world data
Potential repurposing of oncology drugs for the treatment of Alzheimer's disease
Scaffold Searching of FDA and EMA-Approved Drugs Identifies Lead Candidates for Drug Repurposing in Alzheimer’s Disease
Leveraging generative AI to prioritize drug repurposing candidates for Alzheimer’s disease with real-world clinical validation
Repurposing drugs against Alzheimer’s disease: can the anti-multiple sclerosis drug fingolimod (FTY720) effectively tackle inflammation processes in AD?
Repurposing dapagliflozin for Alzheimer's disease: a mechanistic exploration
Network analysis-guided drug repurposing strategies targeting LPAR receptor in the interplay of COVID, Alzheimer’s, and diabetes
Mining on Alzheimer’s diseases related knowledge graph to identity potential AD-related semantic triples for drug repurposing
Reconsidering repurposing: long-term metformin treatment impairs cognition in Alzheimer’s model mice
Alzheimer’s Disease Drug Development Pipeline 2020
In silico repurposing of antipsychotic drugs for Alzheimer’s disease
Artificial intelligence framework identifies candidate targets for drug repurposing in Alzheimer’s disease
High-throughput target trial emulation for Alzheimer’s disease drug repurposing with real-world data
Potential repurposing of oncology drugs for the treatment of Alzheimer's disease
Scaffold Searching of FDA and EMA-Approved Drugs Identifies Lead Candidates for Drug Repurposing in Alzheimer’s Disease
Leveraging generative AI to prioritize drug repurposing candidates for Alzheimer’s disease with real-world clinical validation
Repurposing drugs against Alzheimer’s disease: can the anti-multiple sclerosis drug fingolimod (FTY720) effectively tackle inflammation processes in AD?
Repurposing dapagliflozin for Alzheimer's disease: a mechanistic exploration
Network analysis-guided drug repurposing strategies targeting LPAR receptor in the interplay of COVID, Alzheimer’s, and diabetes
Mining on Alzheimer’s diseases related knowledge graph to identity potential AD-related semantic triples for drug repurposing
Reconsidering repurposing: long-term metformin treatment impairs cognition in Alzheimer’s model mice
Alzheimer’s Disease Drug Development Pipeline 2020
In silico repurposing of antipsychotic drugs for Alzheimer’s disease
Artificial intelligence framework identifies candidate targets for drug repurposing in Alzheimer’s disease
High-throughput target trial emulation for Alzheimer’s disease drug repurposing with real-world data
Potential repurposing of oncology drugs for the treatment of Alzheimer's disease
Scaffold Searching of FDA and EMA-Approved Drugs Identifies Lead Candidates for Drug Repurposing in Alzheimer’s Disease
Leveraging generative AI to prioritize drug repurposing candidates for Alzheimer’s disease with real-world clinical validation
Repurposing drugs against Alzheimer’s disease: can the anti-multiple sclerosis drug fingolimod (FTY720) effectively tackle inflammation processes in AD?
Repurposing dapagliflozin for Alzheimer's disease: a mechanistic exploration
Network analysis-guided drug repurposing strategies targeting LPAR receptor in the interplay of COVID, Alzheimer’s, and diabetes
Mining on Alzheimer’s diseases related knowledge graph to identity potential AD-related semantic triples for drug repurposing
Reconsidering repurposing: long-term metformin treatment impairs cognition in Alzheimer’s model mice